Late complications of choroidal melanoma brachytherapy and possibility of their prevention

Close metadata

Recommended articles:

Epigenetic markers of choroidal melanoma. Russian Annals of Ophthalmology. 2024;(3):5-10

Current views on pathogenesis and treatment of neovascular glaucoma. Russian Annals of Ophthalmology. 2024;(3):110-116

Proton beam therapy and photodynamic therapy in organ-preserving treatment of uveal melanoma. P.A. Herzen Journal of Oncology. 2024;(4):59-65

Complications and the frequency of their occurrence as the criteria of eye preservation after brachytherapy (BT) are presented in literature with inconsistencies due to the assessment being done after varied follow-up periods (1 month to 5—10 years). The evaluation of complications occurring after applying radioiodine can be found in literature. The complications after BT beta particle emitting ophthalmic applicators are seldom discussed in articles. Purpose: to examine the frequency of complications, the characteristics of their development after choroidal melanoma (CM) brachytherapy with ruthenium ophthalmic applicators (OA) during long-term follow-up and determine the possibility of their prevention. Material and methods. Characteristics of postradiation period after BT were studied in 200 patients with CM (200 eyes). Among them, 127 patients were treated by authors of this study, 73 were provided treatment by other specialized medical facilities in Moscow. The study involved 84 male and 116 female patients aged 56.14±12.8 in average. The follow-up periods spanned 2 to 39 years (mean length 9.84±6.16 years). BT was done only with ruthenium OA (beta radiation) manufactured in Russian. Results. Follow-up period after BT for 83% of patients was 5 years. Complications occurred in 68.5% of patients. Complications were found in 74.63% of patients with CM localized pre-equatorially and in 65.4% of patients with CM localized in the posterior part of the eye. Complications associated with radiation-induced injuries in crystalline lens, retina and choroidal blood vessels were more frequent. Conclusions. The frequency of complications depends on the size of CM and its localization. Complications were the least frequent in patients with CM thickness of 5 mm or less.

Keywords:

choroidal melanoma

brachytherapy

brachytherapy complications

radiation neuroretinopathy

radiation maculopathy

neovascular glaucoma

radiation cataract

Authors:

Brovkina A.F.

Russian Medical Academy of Postdegree Education, Moscow, Russia

Khionidi Ya.N.

S.P. Botkin State Clinical Hospital, Branch №1, Moscow Department of Public Health, 7 Mamonovskiy pereulok, Moscow, Russian Federation, 123001

List of references:

Brovkina AF, Zarubey GD. Aboute efficacy of brachytherapy of uveal melanomas. Oftalmologicheskiy zhurnal. 1993;(1):1-4.(In Russ.)
Brovkina AF, Zarubey GD, Valskiy VV. Criteria for assessing the efficacy of brachytherapy of uveal melanomas, complications of therapy and there prevention. Vestnik оftal’mologii. 1997;113(3):14-16. (In Russ.)
Lommatzsch PK, Werschnik C, Schuster E. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2000;238(2):129-137.
Stoffelns BM, Kutzner J Jochem T. Retrospective analysis of ruthenium - 106 brachytherapy for small and medium-sized malignant melanoma of the posterior choroid. Klin.Monatsbl.Augenheilkd. 2002;219(4):216-220. https://doi.org/10.1055/s-2002-30654
Kaiserman N, Kaiserman I, Hendler K, Frenkel S, Pe’er J. Ruthenium-106 plaque brachytheray for thick posterior uveal melanomas. Br J Ophthalmol. 2009;93(9):1167-1171. https://doi.org/10.1136/bjo.2009.157701
Rouberol F, Roy P, Kodjikian L, Gérard JP, Jean-Louis B, Grange JD. Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years’ experience with beta-rays). Am J Ophthalmol. 2004;137(5):893-900. https://doi.org/10.1016/j.ajo.2003.12.032
Browne AW, Dandapani SV, Jennelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy. 2015;14(5):718-725. https://doi.org/10.1016/j.brachy.2015.04.010
Shields CL, Shields JA, Cater J Gündüz K, Miyamoto C, Micaily B, Brady LW. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000;118(9):1219-1228.
Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No 17. Arch Ophthalmol. 2001;119(7):951-965.
Puusaari I, Heikkonen J, Kivelä T. Effect of radiation dose on ocular complications after iodine brachytherapy for large uveal melanoma: empirical data and simulation of collimating plaques. Invest Ophthalmol Vis Sci. 2004;45(10):3425-3434. https://doi.org/10.1167/iovs.04-0066
Vonk DT, Kim Y, Javid C, Gordon JD, Stea B. Prescribing to tumor apex in episcleral plaque iodine-125 brachytherapy for medium-sized choroidal melanoma: A single-institutional retrospective review. Brachytherapy. 2015; 14(5):726-733. https://doi.org/10.1016/j.brachy.2015.05.002
Chang MY, McCannel TA. Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol. 2013;97(7):804-811. https://doi.org/10.1136/bjophthalmol-2012-302490
Zarranz-Ventura J, Salinas-Alamán A, Barrio-Barrio J, de Nova E, Bonet E, García-Layana A. Massive lipid exudation and retinal detachment after combined brachytherapy and transpupillary thermotherapy in choroidal melanoma. Arch Soc Esp Oftalmol. 2013;88(5):197-200. https://doi.org/10.1016/j.oftal.2012.02.012
Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys. 2005;63(1):101-108. https://doi.org/10.1016/j.ijrobp.2005.01.022
Tabandeh H, Chaudhry NA, Murray TG, Ehlies F, Hughes R, Scott IU, Markoe AM. Intraoperative echographic localization of iodine-125 for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2): 199-204.
McCannel TA, Chang MY, Burgess BL. Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology. 2012;119(3):606-610. https://doi.org/10.1016/j.ophtha.2011.08.046
Barker CA, Francis JH, Cohen GN, Marr BP, Wolden SL, McCormick B, Abramson DH. (106)Ru plaque brachytherapy for uveal melanoma: associated factors with local tumor recurrence. Brachytherapy. 2014; 13(6):584-590. https://doi.org/10.1016/j.brachy.2014.04.002
Puusaari I, Heikkonen J, Kivelä T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology. 2004;111(9):1768-1777.
Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye (Lond). 2009;23(6):1254-1268. https://doi.org/10.1038/eye.2009.43
Browne AW, Dandapani SV, Jennelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy. 2015;14(5):718-725. https://doi.org/10.1016/j.brachy.2015.04.010
Ferrufino-Ponce ZK, Henderson BA. Radiotherapy and cataract formation. Semin Ophthalmol. 2006;21(3):171-180. https://doi.org/10.1080/08820530500351728
Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R. New Zealand experience of I¹²⁵ brachytherapy for choroidal melanoma. Clin Experiment Ophthalmol. 2005;33(5):490-494.
Sagoo MS, Shields CL, Emrich J, Mashayekhi A, Komarnicky L, Shields JA. Plaque radiotherapy for juxtapapillary choroidal melanoma: treatment complications and visual outcomes in 650 consecutive cases. JAMA Ophthalmol. 2014;132(6):697-702. https://doi.org/10.1001/jamaophthalmol.2014.111
Pogrzebielski A, Starzycka M, Romanowska-Dixon B, Jakubowska B, Szpakowicz U. The analysis of I125 brachytherapy complications in cases of uveal melanoma. Klin Oczna. 2005;107(1-3):49-53.
Marconi DG, de Castro DG, Rebouças LM, Bernardes Gil GO, Fogaroli RC, Conte Maia MA, Gobo Silva ML, Assis Pellizzon AC, Motono Chojniak MM. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for melanoma. Brachytherapy. 2013;12(3):235-239. https://doi.org/10.1016/j.brachy.2012.01.012
Brovkina AF, Khionidi Ia. N. Cataract as complication of uveal melanomas brachytherapy. Oftalmologicheskie vedomosti. 2011;4(1):58-62. (In Russ.)
Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C, Plancher C, Dendale R, Asselain B Solignac S, Mazal A, Desjardins L. 125I plaque brachytherapy for anterior uveal melanomas. Eye (Lond). 2004;18(9):911-916. https://doi.org/10.1038/sj.eye.6701361
Brovkina AF, Khionidi IaN, Nechesniuk SIu. Mechanism of secondary glaucoma after uveal melanomas brachytherapy. Glaucoma. 2010; 9(1):52-55. (In Russ.)
Toivonen P, Kivelä T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology. 2006;113(5):865-873. https://doi.org/10.1016/j.ophtha.2005.10.059
Brovkina AF, Zargarian AE, Khionidi IaN. Radio-induced maculopathy. Vestnik oftal’mologii. 2012;128(2):3-7. (In Russ.)
Krema H, Heydarian M, Beiki-Ardakani A, Weisbrod D, Xu W, Simpson ER, Sahgal AA comparison between ¹²⁵Iodine brachytherapy and stereotactic radiotherapy in the management of juxtapapillary choroidal melanoma. Br J Ophthalmol. 2013;97(3):327-332. https://doi.org/10.1136/bjophthalmol-2012-302808
Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys. 1993;26(4):613-618.
Heindl LM, Lotter M, Strnad V, Sauer R, Naumann GO, Knorr HL. High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study. Ophthalmologe. 2007;104(2):149-157. https://doi.org/10.1007/s00347-006-1451-1453
Lotayef MM, Othman IS, Shelil AE, Kerima H. Ru106 Brachytherapy for Management of Choroidal Melanoma: Do we Need to Adjust Total dose According to the New NIST Calibration Measurement? J Egypt Natl Canc Inst. 2005;17(3):211-217.
Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy — clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond). 1991;5(Pt 2):239-251. https://doi.org/10.1038/eye.1991.39
Saornil MA, Egan KM, Gragoudas ES, Seddon JM, Walsh SM, Albert DM. Histopathology of proton beam-irradiated vs enucleated uveal melanomas. Arch Ophthalmol. 1992;110(8):1112-1118.
Horgan N, Shields CL, Mashayekhi A, Teixeira LF, Materin MA, Shields JA. Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina. 2008;28(2):263-273. https://doi.org/10.1097/IAE.0b013e31814b1b75
Finger PT, Chin KJ, Yu GP. Palladium-103 for Choroidal Melanoma Study Group. Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol. 2010;149(4):608-615. https://doi.org/10.1016/j.ajo.2009.11.006
Pang CE, Freund KB. Intravitreal polypoidal choroidal vasculopathy in radiation retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2014;45(6):585-588. https://doi.org/10.3928/23258160-20141008-04
Caminal JM, Padrón-Pérez N, Arias L, Masuet-Aumatell C, Gutiérrez C, Piulats JM, Pera J, Català J, Rubio MJ, Arruga J. Transscleral resection without hypotensive anaesthesia vs iodine-125 plaque brachytherapy in the treatment of choroidal melanoma. Eye (Lond). 2016;30(6):833-842. https://doi.org/10.1038/eye.2016.49
Kreusel KM, Bechrakis N, Riese J, Krause L, Wachtlin J, Foerster MH. Combined brachytherapy and transpupillary thermotherapy for large choroidal melanoma: tumor regression and early complications. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1575-1580. https://doi.org/10.1007/s00417-006-0357-8
Ziangirova GG, Antonova OV. Choroidal circulatory disorders in abnormal retinal avascular layer changes. Vestnik oftal’mologii. 2008;124(5):40-44. (In Russ.)
García-Álvarez C, Saornil MA, López-Lara F, Almaraz A, Muñoz MF, Frutos-Baraja J, Muiños Y. Episcleral brachytherapy for uveal melanoma: analysis of 136 cases. Clin Transl Oncol. 2012;14(5):350-355. https://doi.org/10.1007/s12094-012-0807-1
Szuścik I, Romanowska-Dixon B, Markiewicz A, Pogrzebielski A, Jakubowska B Radiation optic neuropathy after the brachytherapy of the uveal melanoma. Klin Oczna. 2006;108(7-9):278-280.
Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol. 2004;32(3):233-235. https://doi.org/10.1111/j.1442-9071.2004.00809.x
Levin LA, Gragoudas ES, Lessell S. Endothelial cell loss in irradiated optic nerves. Ophthalmology. 2000;107(2):370-374.

Close metadata